SynthesisEuropean journal of clinical pharmacology2021
Direct oral anticoagulant safety during breastfeeding: a narrative review.
Synthesis in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Preventing Postpartum Venous Thromboembolism With Low-Molecular-Weight Heparin: The PP-HEP Pilot Randomised Controlled Trial.BJOG : an international journal of obstetrics and gynaecology · 2025Trial
- Antepartum and Postpartum Thromboprophylaxis Preferences: Insights From a Single-Center Survey.Health science reports · 2026Article
- Oral anticoagulation for adults with atrial fibrillation or venous thromboembolism.Australian prescriber · 2025Review
- Exploring barriers to human milk banking acceptability among nursing mothers in Iran using social cognitive perspectives.International breastfeeding journal · 2025Article
- Lactation safety of cardiovascular medications.American heart journal plus : cardiology research and practice · 2025Review
- Venous thromboembolism in pregnancy and postpartum: an illustrated review.Research and practice in thrombosis and haemostasis · 2024Article
- New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline.Neurological research and practice · 2024Article
- Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications.Cells · 2022Review
- Special Considerations for Women of Reproductive Age on Anticoagulation.Journal of general internal medicine · 2022Review
- Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation.Hematology. American Society of Hematology. Education Program · 2021Article
- Article
- Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThere are limited data regarding the safety of direct oral anticoagulants (DOACs) during breastfeeding. The aim of the present study is to investigate the extent of excretion of DOACs into human milk according to the available clinical and experimental studies.
methodsOn 16th January 2021, we systematically searched PubMed, Scopus, Embase, and Web of Science for all studies which investigated DOACs in breastfeeding without any time frame and language limitation. Search keywords were [breastfeeding, breast feeding, breastfed, lactation, milk secretion OR milk] AND [apixaban OR Eliquist OR rivaroxaban OR Xarelto OR edoxaban OR Savaysa OR dabigatran OR Pradaxa OR dabigatran etexilate OR dabigatran etexilate mesylate OR direct oral anticoagulant OR DOAC OR new oral anticoagulant OR NOAC]. Finally, we identified six articles which reported DOAC use during breastfeeding or lactation. RESULTS AND
conclusionAccording to the available limited data, dabigatran has the least excretion in human breast milk. Rivaroxaban and dabigatran both have acceptable milk excretion cutoffs, whereas apixaban milk excretion is greater than the maximum allowed range. Further well-designed studies with larger sample sizes are required to generate consistent comparable data and clarify benefits and risks of each DOAC during breastfeeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.